1b1c › Citations

Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution.

Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP
Protein Sci 8 298-306 (1999)
Cited: 57 times
EuropePMC logo PMID: 10048323

Abstract

The crystal structure of the FMN-binding domain of human NADPH-cytochrome P450 reductase (P450R-FMN), a key component in the cytochrome P450 monooxygenase system, has been determined to 1.93 A resolution and shown to be very similar both to the global fold in solution (Barsukov I et al., 1997, J Biomol NMR 10:63-75) and to the corresponding domain in the 2.6 A crystal structure of intact rat P450R (Wang M et al., 1997, Proc Nat Acad Sci USA 94:8411-8416). The crystal structure of P450R-FMN reported here confirms the overall similarity of its alpha-beta-alpha architecture to that of the bacterial flavodoxins, but reveals differences in the position, number, and length of the helices relative to the central beta-sheet. The marked similarity between P450R-FMN and flavodoxins in the interactions between the FMN and the protein, indicate a striking evolutionary conservation of the FMN binding site. The P450R-FMN molecule has an unusual surface charge distribution, leading to a very strong dipole, which may be involved in docking cytochrome P450 into place for electron transfer near the FMN. Several acidic residues near the FMN are identified by mutagenesis experiments to be important for electron transfer to P4502D6 and to cytochrome c, a clear indication of the part of the molecular surface that is likely to be involved in substrate binding. Somewhat different parts are found to be involved in binding cytochrome P450 and cytochrome c.

Articles - 1b1c mentioned but not cited (12)

  1. Molecular view of an electron transfer process essential for iron-sulfur protein biogenesis. Banci L, Bertini I, Calderone V, Ciofi-Baffoni S, Giachetti A, Jaiswal D, Mikolajczyk M, Piccioli M, Winkelmann J. Proc Natl Acad Sci U S A 110 7136-7141 (2013)
  2. Cytochrome P450 17A1 Interactions with the FMN Domain of Its Reductase as Characterized by NMR. Estrada DF, Laurence JS, Scott EE. J Biol Chem 291 3990-4003 (2016)
  3. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Marohnic CC, Panda SP, McCammon K, Rueff J, Rueff J, Masters BS, Kranendonk M. Drug Metab Dispos 38 332-340 (2010)
  4. Identifying unexpected therapeutic targets via chemical-protein interactome. Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. PLoS One 5 e9568 (2010)
  5. Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase. Udhane SS, Parween S, Kagawa N, Pandey AV. Front Pharmacol 8 580 (2017)
  6. Crystal structure of cindoxin, the P450cin redox partner. Madrona Y, Hollingsworth SA, Tripathi S, Fields JB, Rwigema JC, Tobias DJ, Poulos TL. Biochemistry 53 1435-1446 (2014)
  7. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. Su J, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang H, Li J, Bei Y, Xu J, Zhang M, Zhang Q, Su Z, Huang Y, Pang J, Zhou SF. Drug Des Devel Ther 8 2555-2602 (2014)
  8. Identified the Synergistic Mechanism of Drynariae Rhizoma for Treating Fracture Based on Network Pharmacology. Lin H, Wang X, Wang L, Dong H, Huang P, Cai Q, Mo Y, Huang F, Jiang Z. Evid Based Complement Alternat Med 2019 7342635 (2019)
  9. Calculating ensemble averaged descriptions of protein rigidity without sampling. González LC, Wang H, Livesay DR, Jacobs DJ. PLoS One 7 e29176 (2012)
  10. Three-Dimensional Krawtchouk Descriptors for Protein Local Surface Shape Comparison. Sit A, Shin WH, Kihara D. Pattern Recognit 93 534-545 (2019)
  11. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  12. Single Mutations in Cytochrome P450 Oxidoreductase Can Alter the Specificity of Human Cytochrome P450 1A2-Mediated Caffeine Metabolism. Esteves F, Almeida CMM, Silva S, Saldanha I, Urban P, Rueff J, Pompon D, Truan G, Kranendonk M. Biomolecules 13 1083 (2023)


Reviews citing this publication (7)

  1. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. Drug Metab Rev 41 573-643 (2009)
  2. NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family. Iyanagi T, Xia C, Kim JJ. Arch Biochem Biophys 528 72-89 (2012)
  3. The dual function of flavodiiron proteins: oxygen and/or nitric oxide reductases. Romão CV, Vicente JB, Borges PT, Frazão C, Teixeira M, Teixeira M. J Biol Inorg Chem 21 39-52 (2016)
  4. Dynamic control of electron transfers in diflavin reductases. Aigrain L, Fatemi F, Frances O, Lescop E, Truan G. Int J Mol Sci 13 15012-15041 (2012)
  5. The catalytic function of cytochrome P450 is entwined with its membrane-bound nature. Barnaba C, Gentry K, Sumangala N, Ramamoorthy A. F1000Res 6 662 (2017)
  6. Glyphosate's Synergistic Toxicity in Combination with Other Factors as a Cause of Chronic Kidney Disease of Unknown Origin. Gunatilake S, Seneff S, Orlando L. Int J Environ Res Public Health 16 E2734 (2019)
  7. Electron supply and catalytic oxidation of nitrogen by cytochrome P450 and nitric oxide synthase. Nishida CR, Knudsen G, Straub W, Ortiz de Montellano PR. Drug Metab Rev 34 479-501 (2002)

Articles citing this publication (38)

  1. Single-molecule height measurements on microsomal cytochrome P450 in nanometer-scale phospholipid bilayer disks. Bayburt TH, Sligar SG. Proc Natl Acad Sci U S A 99 6725-6730 (2002)
  2. Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering. Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, Roberts GCK. J Biol Chem 284 36628-36637 (2009)
  3. Plant NADPH-cytochrome P450 oxidoreductases. Jensen K, Møller BL. Phytochemistry 71 132-141 (2010)
  4. Redox-linked domain movements in the catalytic cycle of cytochrome p450 reductase. Huang WC, Ellis J, Moody PC, Raven EL, Roberts GC. Structure 21 1581-1589 (2013)
  5. Four crystal structures of the 60 kDa flavoprotein monomer of the sulfite reductase indicate a disordered flavodoxin-like module. Gruez A, Pignol D, Zeghouf M, Covès J, Fontecave M, Ferrer JL, Fontecilla-Camps JC. J Mol Biol 299 199-212 (2000)
  6. Differences in a conformational equilibrium distinguish catalysis by the endothelial and neuronal nitric-oxide synthase flavoproteins. Ilagan RP, Tiso M, Konas DW, Hemann C, Durra D, Hille R, Stuehr DJ. J Biol Chem 283 19603-19615 (2008)
  7. Nitric-oxide synthase (NOS) reductase domain models suggest a new control element in endothelial NOS that attenuates calmodulin-dependent activity. Knudsen GM, Nishida CR, Mooney SD, Ortiz de Montellano PR. J Biol Chem 278 31814-31824 (2003)
  8. Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego. Fairhead M, Giannini S, Gillam EM, Gilardi G. J Biol Inorg Chem 10 842-853 (2005)
  9. Molecular dynamics simulations give insight into the conformational change, complex formation, and electron transfer pathway for cytochrome P450 reductase. Sündermann A, Oostenbrink C. Protein Sci 22 1183-1195 (2013)
  10. The X-ray structure of the FMN-binding protein AtHal3 provides the structural basis for the activity of a regulatory subunit involved in signal transduction. Albert A, Martínez-Ripoll M, Espinosa-Ruiz A, Yenush L, Culiáñez-Macià FA, Serrano R. Structure 8 961-969 (2000)
  11. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, Denny WA. J Med Chem 51 6853-6865 (2008)
  12. Fusion of Ferredoxin and Cytochrome P450 Enables Direct Light-Driven Biosynthesis. Mellor SB, Nielsen AZ, Burow M, Motawia MS, Jakubauskas D, Møller BL, Jensen PE. ACS Chem Biol 11 1862-1869 (2016)
  13. A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs. Prade E, Mahajan M, Im SC, Zhang M, Gentry KA, Anantharamaiah GM, Waskell L, Ramamoorthy A. Angew Chem Int Ed Engl 57 8458-8462 (2018)
  14. Inhibition of NADPH cytochrome P450 reductase by the model sulfur mustard vesicant 2-chloroethyl ethyl sulfide is associated with increased production of reactive oxygen species. Gray JP, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Toxicol Appl Pharmacol 247 76-82 (2010)
  15. Association of cytochrome P450 enzymes is a determining factor in their catalytic activity. Hazai E, Bikádi Z, Simonyi M, Kupfer D. J Comput Aided Mol Des 19 271-285 (2005)
  16. Kinetic and structural characterization of the interaction between the FMN binding domain of cytochrome P450 reductase and cytochrome c. Huang R, Zhang M, Rwere F, Waskell L, Ramamoorthy A. J Biol Chem 290 4843-4855 (2015)
  17. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Allorge D, Bréant D, Harlow J, Chowdry J, Lo-Guidice JM, Chevalier D, Cauffiez C, Lhermitte M, Blaney FE, Tucker GT, Broly F, Ellis SW. Proteins 59 339-346 (2005)
  18. High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M. Pharmacogenomics J 14 343-349 (2014)
  19. The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners. Esteves F, Campelo D, Gomes BC, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G, Kranendonk M. Front Pharmacol 11 299 (2020)
  20. Catalytically functional flavocytochrome chimeras of P450 BM3 and nitric oxide synthase. Fuziwara S, Sagami I, Rozhkova E, Craig D, Noble MA, Munro AW, Chapman SK, Shimizu T. J Inorg Biochem 91 515-526 (2002)
  21. Flavodoxin cofactor binding induces structural changes that are required for protein-protein interactions with NADP(+) oxidoreductase and pyruvate formate-lyase activating enzyme. Crain AV, Broderick JB. Biochim Biophys Acta 1834 2512-2519 (2013)
  22. Impeded electron transfer from a pathogenic FMN domain mutant of methionine synthase reductase and its responsiveness to flavin supplementation. Gherasim CG, Zaman U, Raza A, Banerjee R. Biochemistry 47 12515-12522 (2008)
  23. Solution structure of the cytochrome P450 reductase-cytochrome c complex determined by neutron scattering. Freeman SL, Martel A, Devos JM, Basran J, Raven EL, Roberts GCK. J Biol Chem 293 5210-5219 (2018)
  24. Rice P450 reductases differentially affect P450-mediated metabolism in bacterial expression systems. Park S, Kim YS, Rupasinghe SG, Schuler MA, Back K. Bioprocess Biosyst Eng 36 325-331 (2013)
  25. Coupling of Redox and Structural States in Cytochrome P450 Reductase Studied by Molecular Dynamics Simulation. Iijima M, Ohnuki J, Sato T, Sugishima M, Takano M. Sci Rep 9 9341 (2019)
  26. Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding. Esteves F, Urban P, Rueff J, Truan G, Kranendonk M. Int J Mol Sci 21 E6669 (2020)
  27. Outer membrane cytochromes/flavin interactions in Shewanella spp.-A molecular perspective. Babanova S, Matanovic I, Cornejo J, Bretschger O, Nealson K, Atanassov P. Biointerphases 12 021004 (2017)
  28. Rainbow tags: a visual tag system for recombinant protein expression and purification. Finn RD, Kapelioukh I, Paine MJ. Biotechniques 38 387-8, 390-2 (2005)
  29. Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase. Parween S, Rojas Velazquez MN, Udhane SS, Kagawa N, Pandey AV. Front Pharmacol 10 1187 (2019)
  30. Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. Arendse LB, Blackburn JM. Sci Rep 8 11876 (2018)
  31. Exhaustive computational search of ionic-charge clusters that mediate interactions between mammalian cytochrome P450 (CYP) and P450-oxidoreductase (POR) proteins. Zawaira A, Gallotta M, Beeton-Kempen N, Coulson L, Marais P, Kuttel M, Blackburn J. Comput Biol Chem 34 42-52 (2010)
  32. Nanodisc reconstitution of flavin mononucleotide binding domain of cytochrome-P450-reductase enables high-resolution NMR probing. Krishnarjuna B, Yamazaki T, Anantharamaiah GM, Ramamoorthy A. Chem Commun (Camb) 57 4819-4822 (2021)
  33. Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. LinWu SW, Wang AH, Peng FC. Expert Opin Drug Metab Toxicol 6 967-981 (2010)
  34. Detection of a novel severe mutation affecting the CYP21A2 gene in a Chilean male with salt wasting congenital adrenal hyperplasia. Arteaga E, Valenzuela F, Lagos CF, Lagos M, Martinez A, Baudrand R, Carvajal C, Fardella CE. Endocrine 67 258-263 (2020)
  35. Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain. Burris-Hiday SD, Scott EE. J Biol Chem 299 105112 (2023)
  36. Characterization of a Virally Encoded Flavodoxin That Can Drive Bacterial Cytochrome P450 Monooxygenase Activity. Lamb DC, Goldstone JV, Zhao B, Lei L, Mullins JGL, Allen MJ, Kelly SL, Stegeman JJ. Biomolecules 12 1107 (2022)
  37. Cloning and Functional Characterization of NADPH-Cytochrome P450 Reductases in Aconitum vilmorinianum. Cheng J, Li G, Wang X, Yang C, Xu F, Qian Z, Ma X. Molecules 28 7409 (2023)
  38. Thermodynamic Driving Forces of Redox-Dependent CPR Insertion into Biomimetic Endoplasmic Reticulum Membranes. Martinez MJ, Carder JD, Taylor EL, Jacobo EP, Kang C, Brozik JA. J Phys Chem B 126 1691-1699 (2022)


Related citations provided by authors (1)

  1. Crystallization and Preliminary X-Ray Diffraction Studies of Human Cytochrome P450 Reductase. Zhao Q, Smith G, Modi S, Paine M, Wolf RC, Tew D, Lian LY, Primrose WU, Roberts GC, Driessen HP J. Struct. Biol. 116 320-325 (1996)

Quick links